Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Featured Article Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsSubmitted by Nathan Reiff. Date Posted: 3/12/2026. 
Summary - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to grow to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with tailored mechanisms. Fortunately, a number of promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two smaller biotech companies are enjoying notable share-price momentum thanks to their leading oncology medicines. Beyond therapeutic promise, these drugs could help the firms move toward greater stability and, potentially, long-term profitability. That said, both remain high-risk investments: each faces clinical, regulatory, or commercial hurdles that could limit upside even as the rewards for success are substantial. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.
Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.
With $6.4M in sales in just four years, they're getting ready for the next step. Become a Med-X Shareholder Before Their Nasdaq Plans Unfold Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, jumping nearly 37% in a week when the S&P 500 slipped about 1%. That rally added to IOVA's strong year-to-date performance, with shares more than doubling so far. Still, with a consensus price target of $8.88, Wall Street sees further upside—implying roughly 71% more gains from current levels. The main catalyst behind Iovance's move is its lead therapy, Amtagvi, a T‑cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is building commercial momentum, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL‑2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak annual U.S. sales. Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track designation for non‑small cell lung cancer and is being evaluated for other tumor types. Some of Iovance's outperformance this year also reflects its Q4 2025 earnings report, issued in late February, in which the company posted narrower‑than‑expected losses per share and reported $5 million in revenue. For the full year, revenue rose roughly 30% year over year. Iovance is still considered a small (about $2 billion) biotech, and despite the rally, analysts remain cautious—about half of its roughly dozen ratings are Hold or Sell. Risks are significant: in addition to typical small‑biotech concerns, Amtagvi is a personalized therapy that is costly and complex to manufacture. That manufacturing profile could constrain margins and profitability even as demand increases. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year‑to‑date performance far outpaces Iovance's. IBRX shares are up nearly 300% in 2026, and analysts remain optimistic: the consensus price target is $13.60, roughly 70% above the stock's current level. ImmunityBio's primary growth driver is Anktiva, a treatment for certain forms of bladder cancer. In February, shares jumped after the E.U. regulator granted conditional marketing authorization—one of several recent approvals globally. Anktiva is already material to the company's top line: the drug generated $113 million in sales last year, a roughly 700% year‑over‑year increase. Like Amtagvi, Anktiva may have potential in other cancer indications, and ImmunityBio is actively exploring additional regulatory designations. Despite the strong recent performance, IBRX remains speculative and risky. The company reported a full‑year net loss of $351 million for 2025 as R&D and other expenses remain elevated. Analysts, however, are relatively bullish on ImmunityBio compared with Iovance: six out of seven covering the stock rate it a Buy or equivalent.
| 
